Ascent Group, LLC Abb Vie Inc. Transaction History

Ascent Group, LLC

$1.29 Billion
Q3 2024

A detailed history of Ascent Group, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Ascent Group, LLC holds 24,547 shares of ABBV stock, worth $4.31 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares

24,547

Previous 25,778 4.78%

Holding current value

$4.31 Million

Previous $4.42 Million 9.64%

% of portfolio

0.37%

Previous 0.37%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $201,687 - $245,375	-1,231 Reduced 4.78%	24,547 $4.85 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $170,578 - $199,197	1,102 Added 4.47%	25,778 $4.42 Million
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $1.24 Million - $1.42 Million	7,787 Added 46.11%	24,676 $4.49 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $250,294 - $281,890	1,819 Added 12.07%	16,889 $2.62 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $1.04 Million - $1.2 Million	-7,787 Reduced 34.07%	15,070 $2.25 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $166,565 - $207,279	1,257 Added 5.82%	22,857 $3.08 Million
Q1 2023 May 10, 2023	BUY	$144.61 - $166.54 $1.69 Million - $1.94 Million	11,667 Added 117.46%	21,600 $3.44 Million
Q4 2022 Feb 16, 2023	BUY	$138.31 - $165.87 $134,575 - $161,391	973 Added 10.86%	9,933 $1.61 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $641,523 - $735,785	4,780 Added 114.35%	8,960 $1.31 Million
Q2 2022 Aug 05, 2022	BUY	$137.62 - $174.96 $130,601 - $166,037	949 Added 29.37%	4,180 $600,000
Q1 2022 May 10, 2022	BUY	$131.98 - $163.75 $32,467 - $40,282	246 Added 8.24%	3,231 $524,000
Q4 2021 Mar 01, 2022	BUY	$107.43 - $135.93 $320,678 - $405,751	2,985 New	2,985 $394,000

Others Institutions Holding ABBV

# of Institutions

3,852

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ascent Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ascent Group, LLC with notifications on news.

Account